Organon & Co banner

Organon & Co
F:7XP

Watchlist Manager
Organon & Co Logo
Organon & Co
F:7XP
Watchlist
Price: 11.835 EUR -0.04% Market Closed
Market Cap: €3B

Wall St Price Targets

7XP Price Targets Summary
Organon & Co

Wall Street analysts forecast 7XP stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 7XP is 6.379 EUR with a low forecast of 4.679 EUR and a high forecast of 8.512 EUR.

Lowest Forecast
Price Target
4.679 EUR
60% Downside
Average Forecast
Price Target
6.379 EUR
46% Downside
Highest Forecast
Price Target
8.512 EUR
28% Downside
Organon & Co Competitors:
Price Targets
PACB
Pacific Biosciences of California Inc
52% Upside
KRUS
Kura Sushi USA Inc
36% Upside

Revenue
Forecast

-6% / Year
Past Growth
1% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
-6% / Year
Past Growth
1% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 7 years, the compound annual growth rate for Revenue has been -6%. The projected CAGR for the next 3 years is 1%.

Gross Profit
Forecast

-6% / Year
Past Growth
4% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss
-6% / Year
Past Growth
4% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Over the last 7 years, the compound annual growth rate for Gross Profit has been -6%. The projected CAGR for the next 3 years is 4%.

Operating Income
Forecast

-10% / Year
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
-19%
Average Miss
-10% / Year
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
-19%
Average Miss

Over the last 7 years, the compound annual growth rate for Operating Income has been -10%. The projected CAGR for the next 3 years is 10%.

Pre-Tax Income
Forecast

-23% / Year
Past Growth
48% / Year
Estimated Growth
Estimates Accuracy
-37%
Average Miss
-23% / Year
Past Growth
48% / Year
Estimated Growth
Estimates Accuracy
-37%
Average Miss

Over the last 7 years, the compound annual growth rate for Pre-Tax Income has been -23%. The projected CAGR for the next 3 years is 48%.

Net Income
Forecast

-29% / Year
Past Growth
78% / Year
Estimated Growth
Estimates Accuracy
-20%
Average Miss
-29% / Year
Past Growth
78% / Year
Estimated Growth
Estimates Accuracy
-20%
Average Miss

Over the last 7 years, the compound annual growth rate for Net Income has been -29%. The projected CAGR for the next 3 years is 78%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 7XP's stock price target?
Price Target
6.379 EUR

According to Wall Street analysts, the average 1-year price target for 7XP is 6.379 EUR with a low forecast of 4.679 EUR and a high forecast of 8.512 EUR.

What is the Revenue forecast for Organon & Co?
Projected CAGR
1%

Over the last 7 years, the compound annual growth rate for Revenue has been -6%. The projected CAGR for the next 3 years is 1%.

What is the Gross Profit forecast for Organon & Co?
Projected CAGR
4%

Over the last 7 years, the compound annual growth rate for Gross Profit has been -6%. The projected CAGR for the next 3 years is 4%.

What is the Operating Income forecast for Organon & Co?
Projected CAGR
10%

Over the last 7 years, the compound annual growth rate for Operating Income has been -10%. The projected CAGR for the next 3 years is 10%.

What is the Pre-Tax Income forecast for Organon & Co?
Projected CAGR
48%

Over the last 7 years, the compound annual growth rate for Pre-Tax Income has been -23%. The projected CAGR for the next 3 years is 48%.

What is the Net Income forecast for Organon & Co?
Projected CAGR
78%

Over the last 7 years, the compound annual growth rate for Net Income has been -29%. The projected CAGR for the next 3 years is 78%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett